Pharmacoeconomics of available treatment options for metastatic prostate cancer

PharmacoEconomics

Volumn 25, Issue 4, 2007, Pages 309-327

  Zeliadt, Steven B ^a   Penson, David F ^a,b,c  

^a USA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Department of Urology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; DIETHYLSTILBESTROL; DOCETAXEL; ESTRADIOL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MITOXANTRONE; NILUTAMIDE; PLACEBO; PREDNISONE; STRONTIUM 89; ZOLEDRONIC ACID;

BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG COST; DRUG MECHANISM; ECONOMIC ASPECT; HEALTH CARE COST; HORMONE SENSITIVITY; HUMAN; META ANALYSIS; METASTASIS; MONOTHERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; ECONOMICS, PHARMACEUTICAL; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 34247275923     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725040-00004     Document Type: Review

References (100)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56 (2): 106-30
2. Penson DF, Chan JM. Prostate cancer. In: Litwin MS, Saigal CS, editors. Urologic diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2007; NIH Publication No. 07-5512: 71-122
3. American Cancer Society. Cancer facts and figures 2007. Atlanta (GA): American Cancer Society, 2007
4. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293 (17): 2095-101
5. Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003; 62 (5): 866-71
6. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941 (1): 293-97
7. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168 (1): 9-12
8. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294 (2): 238-44
9. Loblaw D, Mendelson D, Talcott J, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Onc 2004; 22 (14): 2927-41
10. Seidenfeld J, Samson DJ, Aronson N, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 1999 (4): i-x, 1-246, I1-36, passim
11. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20 (19): 3972-82
12. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14 (6): 1756-64
13. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-12
14. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-20
15. Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol 2006; 16 (3): 138-45
16. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER: Medicare data. Med Care 2002; 40 (8 Suppl.): 104-17
17. Turini M, Redaelli A, Gramegna P, et al. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 2003; 21 (8): 527-41
18. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87 (6): 417-26
19. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360 (9327): 103-6
20. Medical Research Council. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79 (2): 235-46
21. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341 (24): 1781-8
22. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003; 41 (1): 153-64
23. Kramer KM, Bennett CL, Pickard AS, et al. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer 2005; 4 (1): 15-23
24. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003; 56 (4): 317-25
25. Clark JA, Wray N, Brody B, et al. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med 1997; 45 (8): 1299-309
26. Sanford EJ, Paulson DF, Rohner TJ Jr, et al. The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol 1977; 118 (6): 1019-21
27. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132 (7): 566-77
28. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95 (2): 361-76
29. Schellhammer PF. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology 1996; 47 (5): 622-8
30. Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997; 31 (1): 65-75
31. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321 (7): 419-24
32. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998; 33 (2): 144-51
33. Dijkman GA, Janknegt RA, De Reijke TM, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997; 158 (1): 160-3
34. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149 (1): 77-82; discussion 83
35. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339 (15): 1036-42
36. Iversen P, Rasmussen F, Klarskov P, et al. Long-term results of Danish Prostatic Cancer Group trial 86: goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 1993; 72 (12 Suppl.): 3851-4
37. Tyrrell CJ, Altwein JE, Klippel F, et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer: the International Prostate Cancer Study Group. J Urol 1991; 146 (5): 1321-6
38. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355 (9214): 1491-8
39. Cox MC, Dahut WL, Figg WD. The use of thalidomide in androgen-independent prostate cancer. Urol Oncol 2006; 24 (3): 246-9
40. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy: part II. Treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol 2005; 15 (3): 187-95
41. Goodin S, Medina P, Capanna T, et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005; 23 (15): 3352-7
42. Measuring Worth.Com. Five ways to compute the relative value of a US dollar amount, 1790-2005 [online]. Available from URL: http://www. measuringworth.com/calculators/compare/#; [Accessed 2007 Mar 20]
43. Economic History Services. What was the exchange rate then? [online]. Available from URL: http://eh.net/hmit/exchangerates/ [Accessed 2007 Mar 20]
44. Shahinian VB, Kuo YF, Freeman JL, et al. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98 (12): 839-45
45. Bonzani RA, Stricker HJ, Peabody JO, et al. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. J Urol 1998; 160 (6 Pt 2): 2446-9
46. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000; 92 (21): 1731-9
47. Hillner BE, McLeod DG, Crawford ED, et al. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995; 45 (4): 633-40
48. Nicol DL, Heathcote PS, Kateley GD, et al. Advanced prostate cancer: the role of high priced hormone therapy. Med J Aust 1993; 159 (1): 16-9
49. Bennett CL, Matchar D, McCrory D, et al. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer 1996; 77 (9): 1854-61
50. Penson DF, Ramsey S, Veenstra D, et al. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol 2005; 174 (2): 547-52; discussion 552
51. Ramsey S, Veenstra D, Clarke L, et al. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 2005; 66 (4): 835-9
52. Beemsterboer PM, de Koning HJ, Birnie E, et al. Advanced prostate cancer: course, care, and cost implications. Prostate 1999; 40 (2): 97-104
53. Henriksson P, Stege R. Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer. Int J Technol Assess Health Care 1991; 7 (2): 220-5
54. Nygard R, Norum J, Due J. Goserelin (zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res 2001; 21 (1B): 781-8
55. Lucas MD, Strijdom SC, Berk M, et al. Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer. Scand J Urol Nephrol 1995; 29 (4): 497-500
56. Incrocci L, Hop WC, Wijnmaalen A, et al. Treatment outcome, body image, and sexual functioning after orchiectomy and radiotherapy for stage I-II testicular seminoma. Int J Radiat Oncol Biol Phys 2002; 53 (5): 1165-73
57. Williams G, Lindsay S, Bowsher WG. Randomised crossover trial to assess the tolerability of LHRH analogue administration. Prostate Cancer Prostatic Dis 2003; 6 (2): 187-9
58. Byar D, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urologic Research Group Studies. National Cancer Institute Monograph 1988; 7: 165
59. Ockrim JL, Lalani EN, Laniado ME, et al. Transdermal estradiol therapy for advanced prostate cancer: forward to the past? J Urol 2003; 169 (5): 1735-7
60. Drugstore.Com. Lupron depot [online]. Available from URL: http://www.drugstore.com/pharmacy/prices/drug-price.asp?ndc=00300334601&trx= 175006 [Accessed 2007 Mar 19]
61. Doctors Foster and Smith™. Diethylstilbestrol (DES) capsules (generic) [online]. Available from URL: http://www.drsfoster-smith.com/product/ prod_display.cfm?siteid=0&pca-tid=11857& rxpid=27903_90 [Accessed 2007 Mar 15]
62. Drugstore.Com. Casodex [online]. Available from URL: http://www. drugstore.com/pharmacy/prices/drugprice.asp?ndc=00310070530&trx=175006 [Accessed 2007 Mar 20]
63. Chang SS, Benson MC, Campbell SC, et al. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 2005; 103 (1): 11-21
64. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005; 23 (32): 8247-52
65. Sze WM, Shelley MD, Held I, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. A systematic review of randomised trials. Clin Oncol (R Coll Radiol) 2003; 15 (6): 345-52
66. Malmberg I, Persson U, Ask A, et al. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Urology 1997; 50 (5): 747-53
67. McEwan AJ, Amyotte GA, McGowan DG, et al. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur Urol 1994; 26 Suppl. 1: 26-31
68. Shah Syed GM, Maken RN, Muzzaffar N, et al. Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nucl Med Commun 1999; 20 (8): 697-702
69. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44 (5): 519-26
70. Roque M, Martinez MJ, Alonso P, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2003 (4): CD003347
71. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60 (5): 1373-8
72. Bloomfield DJ, Krahn MD, Neogi T, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol 1998; 16 (6): 2272-9
73. Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004; 171 (4): 1537-42
74. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004; 31 (2): 331-52
75. Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006; 17 (7): 1072-82
76. National Institute for Health and Clinical Excellence. Prostate cancer (hormone-refractory): docetaxel. Analysis of cost impact. London: National Institute for Health and Clinical Excellence, 2006
77. Nair B, Wilt T, MacDonald R, et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002 (1): CD003506
78. Konski A, Sherman E, Krahn M, et al. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys 2005; 63 (3): 788-94
79. Konski A, Watkins-Bruner D, Brereton H, et al. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 2006; 106 (1): 51-7
80. Samant RS, Dunscombe PB, Roberts GH. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urol Oncol 2003; 21 (3): 171-7
81. Neymark N, Adriaenssen I, Gorlia T, et al. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur J Cancer 2001; 37 (14): 1768-74
82. Neymark N, Adriaenssen I, Gorlia T, et al. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 2002; 11 (3): 233-48
83. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337 (5): 295-300
84. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15 (3): 1013-21
85. Pilepich MV. Phase III trial of androgen suppression adjuvant to definitive radiotherapy: long-term results of RTOG study 85-31. American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago
86. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292 (7): 821-7
87. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6 (11): 841-50
88. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004; 171 (4): 1393-401
89. Zeliadt SB, Potosky AL, Etzioni R, et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 2004; 64 (6): 1171-6
90. Lyne JC. Medicare reform and your practice: what you need to know. Urology 2004; 64 (5 Suppl. 1): 2-7; discussion 15-18
91. Hillner BE, Roberts JD. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer. J Natl Cancer Inst 2000; 92 (21): 1704-6
92. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90 (20): 1537-44
93. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365-76
94. Ramsey SD, Zeliadt SB, Hall IJ, et al. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. Cancer 2007. In press
95. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30 (6): 473-83
96. Feeny DH. The roles for preference-based measures in support of cancer research and policy. In: Lipscomb J, Gotay C, Snyder C, editors. Outcomes assessment in cancer: measures, methods, and applications. Cambridge: Cambridge University Press, 2005
97. Kind P. The EuroQol instrument: an index of health related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven Press, 1996
98. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35 (11): 1095-108
99. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24 (27): 4448-56
100. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58 (2 Suppl. 1): 101-7